Biology of Blood and Marrow Transplantation
Volume 14, Issue 7 , Pages 783-789 , July 2008

Addition of Infliximab to Standard Acute Graft-versus-Host Disease Prophylaxis following Allogeneic Peripheral Blood Cell Transplantation

  • Mehdi Hamadani

      Affiliations

    • Division of Hematology & Oncology, Arthur G. James Cancer Hospital, The Ohio State University Comprehensive Cancer Center, Columbus, OH
    • ,
  • Craig C. Hofmeister

      Affiliations

    • Division of Hematology & Oncology, Arthur G. James Cancer Hospital, The Ohio State University Comprehensive Cancer Center, Columbus, OH
    • ,
  • Buffy Jansak

      Affiliations

    • Division of Hematology & Oncology, Arthur G. James Cancer Hospital, The Ohio State University Comprehensive Cancer Center, Columbus, OH
    • ,
  • Gary Phillips

      Affiliations

    • Ohio State University, Center for Biostatistics, Columbus, OH
    • ,
  • Patrick Elder

      Affiliations

    • Division of Hematology & Oncology, Arthur G. James Cancer Hospital, The Ohio State University Comprehensive Cancer Center, Columbus, OH
    • ,
  • William Blum

      Affiliations

    • Division of Hematology & Oncology, Arthur G. James Cancer Hospital, The Ohio State University Comprehensive Cancer Center, Columbus, OH
    • ,
  • Sam Penza

      Affiliations

    • Division of Hematology & Oncology, Arthur G. James Cancer Hospital, The Ohio State University Comprehensive Cancer Center, Columbus, OH
    • ,
  • Thomas S. Lin

      Affiliations

    • Division of Hematology & Oncology, Arthur G. James Cancer Hospital, The Ohio State University Comprehensive Cancer Center, Columbus, OH
    • ,
  • Rebecca Klisovic

      Affiliations

    • Division of Hematology & Oncology, Arthur G. James Cancer Hospital, The Ohio State University Comprehensive Cancer Center, Columbus, OH
    • ,
  • Guido Marcucci

      Affiliations

    • Division of Hematology & Oncology, Arthur G. James Cancer Hospital, The Ohio State University Comprehensive Cancer Center, Columbus, OH
    • ,
  • Sherif S. Farag

      Affiliations

    • Division of Hematology and Oncology, Indiana University School of Medicine, Indianapolis, IN
    • These authors contributed equally to this manuscript
    • ,
  • Steven M. Devine

      Affiliations

    • Division of Hematology & Oncology, Arthur G. James Cancer Hospital, The Ohio State University Comprehensive Cancer Center, Columbus, OH
    • These authors contributed equally to this manuscript
    • Corresponding Author InformationCorrespondence and reprint requests: Steven M. Devine, MD, Ohio State University, 320 West 10th Avenue, Columbus, OH 43210.

Received 11 March 2008 ,Accepted 14 April 2008.

  • Image Result

    Cumulative incidence of acute grade II-IV GVHD (black and gray curves depict infliximab-treated and control groups, respectively) Gray's test P-value = .77.

    Cumulative incidence of acute grade II-IV GVHD (black and gray curves depict infliximab-treated and control groups, respectively) Gray's test P-value = .77.

  • Image Result

    Kaplan-Meier estimates of OS (black and gray curves depict infliximab-treated and control groups, respectively) Log-rank P-value = .43.

    Kaplan-Meier estimates of OS (black and gray curves depict infliximab-treated and control groups, respectively) Log-rank P-value = .43.

  • Image Result

    Kaplan-Meier estimates of PFS (black and gray curves depict infliximab-treated and control groups, respectively) Log-rank P-value = .50.

    Kaplan-Meier estimates of PFS (black and gray curves depict infliximab-treated and control groups, respectively) Log-rank P-value = .50.

PII: S1083-8791(08)00150-X

doi: 10.1016/j.bbmt.2008.04.006

Biology of Blood and Marrow Transplantation
Volume 14, Issue 7 , Pages 783-789 , July 2008

Article Tools

* Image Usage & Resolution